CCRL1 Antikörper (PE)

Produktnummer ABIN2662412

Der PE-konjugierte Maus Monoklonal anti-CCRL1 Antikörper (Klon 13E11) (ABIN2662412) detektiert spezifisch CCRL1 in FACS. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für CCRL1 Antikörper (PE) (ABIN2662412)

Target: CCRL1 (Chemokine (C-C Motif) Receptor-Like 1 (CCRL1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CCRL1 Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS)

Klon: 13E11

Produktdetails anti-CCRL1 Antikörper (PE)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu CCRL1

Target: CCRL1 (Chemokine (C-C Motif) Receptor-Like 1 (CCRL1))

Andere Bezeichnung: CCX-CKR

Hintergrund: Human CCX-CKR, also known as CCRL1, is a 40 kD, G-protein-coupled, seven transmembrane receptor. CCRL1 is a decoy receptor for CCL2, CCL8, CCL13, CCL19, CCL21 and CCL25 that regulates chemotaxis of lymphocytes and cancer cells. Chemokine binding by CCX-CKR causes its internalization, reducing levels of available chemokine, and thus regulating migration of lymphocytes and cancerous cells. CCX-CKR is expressed by stromal cells of skin-draining lymph nodes, thymic epithelial cells, and immature dendritic cells (DCs). A low CCX-CKR expression in tumor cells correlates with a poor survival rate of breast cancer patients.